Vitamin price fixing
This article was originally published in The Tan Sheet
Executive Summary
European Commission levies $751.3 mil. fine against eight firms Nov. 21 "for participating in...distinct secret market-sharing and price-fixing cartels affecting vitamin product" from September 1989 to February 1999. Firms charged are Hoffmann-La Roche, BASF, Aventis, Merck KgaA, Solvay Pharmaceuticals, Daiichi Pharmaceutical, Eisai and Takeda Chemical Industries. Since Hoffmann-La Roche "participated in all the cartels," it received the highest fine of $405.9 mil. (1 Euro=$.878). EC decision comes roughly two years after the U.S. Department of Justice levied criminal fines of more than $850 mil. (1"The Tan Sheet" Sept. 13, 1999, p. 4)...
You may also be interested in...
Citric acid price fixing
Five suppliers fined $120.5 mil. (€1=$.887) by European Commission for anti-competitive, market-sharing practices from 1991-1997, EC announces Dec. 5. Firms involved are Archer Daniels Midland, Haarmann & Reimer, Cerestar Bioproducts, Hoffmann-La Roche and Jungbunzlauer. Roche incurred largest portion, roughly $56.3 mil. Each firm was charged in proportion to its size, market share, "gravity" and "duration" of infringement, EC notes. Fines for ADM ($35.5 mil.) and Roche were increased because they acted as cartel co-leaders. Roche recently was fined more than $400 mil. by EC as one of eight firms in separate vitamin price-fixing cartel (1"The Tan Sheet" Nov. 26, In Brief)...
Takeda, Eisai, Daiichi Plead Guilty In Criminal "Vitamin Cartel" Case
Three Japanese vitamin manufacturers have agreed to plead guilty to charges associated with "a worldwide conspiracy to raise and fix prices and allocate market shares for certain vitamins sold in the U.S. and elsewhere," the Department of Justice announced Sept. 9.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”